inmune bio inc - INMB
INMB
Close Chg Chg %
2.51 0.01 0.40%
Open Market
2.52
+0.01 (0.40%)
Volume: 176.08K
Last Updated:
Sep 9, 2026, 1:57 PM EDT
Company Overview: inmune bio inc - INMB
INMB Key Data
| Open $2.55 | Day Range 2.47 - 2.58 |
| 52 Week Range 1.09 - 2.60 | Market Cap $67.72M |
| Shares Outstanding 27.75M | Public Float 24.62M |
| Beta 0.94 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.69 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 339.38K |
INMB Performance
| 1 Week | 2.87% | ||
| 1 Month | 20.38% | ||
| 3 Months | 102.42% | ||
| 1 Year | 24.88% | ||
| 5 Years | -88.27% |
INMB Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
3
Full Ratings ➔
About inmune bio inc - INMB
INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.
INMB At a Glance
INmune Bio, Inc.
225 NE Mizner Boulevard
Boca Raton, Florida 33432
| Phone | 1-561-710-0512 | Revenue | 50.00K | |
| Industry | Biotechnology | Net Income | -45,933,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 257.143% | |
| Fiscal Year-end | 12 / 2026 | Employees | 21 | |
| View SEC Filings |
INMB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 772.435 |
| Price to Book Ratio | 1.763 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.484 |
| Enterprise Value to Sales | 298.095 |
| Total Debt to Enterprise Value | 0.069 |
INMB Efficiency
| Revenue/Employee | 2,380.952 |
| Income Per Employee | -2,187,285.714 |
| Receivables Turnover | 0.011 |
| Total Asset Turnover | 0.001 |
INMB Liquidity
| Current Ratio | 3.551 |
| Quick Ratio | 3.551 |
| Cash Ratio | 2.941 |
INMB Profitability
| Gross Margin | -68.00 |
| Operating Margin | -61,738.00 |
| Pretax Margin | -91,866.00 |
| Net Margin | -91,866.00 |
| Return on Assets | -127.746 |
| Return on Equity | -165.164 |
| Return on Total Capital | -187.039 |
| Return on Invested Capital | -163.242 |
INMB Capital Structure
| Total Debt to Total Equity | 4.396 |
| Total Debt to Total Capital | 4.21 |
| Total Debt to Total Assets | 3.196 |
| Long-Term Debt to Equity | 1.747 |
| Long-Term Debt to Total Capital | 1.674 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Inmune Bio Inc - INMB
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 374.00K | 155.00K | 14.00K | 50.00K | |
Sales Growth
| +106.63% | -58.56% | -90.97% | +257.14% | |
Cost of Goods Sold (COGS) incl D&A
| - | - | - | 84.00K | - |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | - | - | 84.00K | - |
Depreciation
| - | - | - | 84.00K | - |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | - | - | - |
Gross Income
| - | - | - | (34.00K) | - |
Gross Income Growth
| - | - | - | - | - |
Gross Profit Margin
| - | - | - | -68.00% | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 26.32M | 29.90M | 42.65M | 30.84M | |
Research & Development
| 17.07M | 20.27M | 33.17M | 20.66M | |
Other SG&A
| 9.26M | 9.62M | 9.48M | 10.18M | |
SGA Growth
| -10.26% | +13.57% | +42.66% | -27.70% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 15.91M | - |
EBIT after Unusual Expense
| (25.95M) | (29.74M) | (42.63M) | (46.78M) | |
Non Operating Income/Expense
| (1.35M) | (267.00K) | 553.00K | 850.00K | |
Non-Operating Interest Income
| - | - | - | 850.00K | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (27.30M) | (30.01M) | (42.08M) | (45.93M) | |
Pretax Income Growth
| +10.02% | -9.92% | -40.24% | -9.15% | |
Pretax Margin
| -7,299.20% | -19,360.00% | -300,585.71% | -91,866.00% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (27.30M) | (30.01M) | (42.08M) | (45.93M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (27.30M) | (30.01M) | (42.08M) | (45.93M) | |
Net Income Growth
| +10.02% | -9.92% | -40.24% | -9.15% | |
Net Margin Growth
| -7,299.20% | -19,360.00% | -300,585.71% | -91,866.00% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (27.30M) | (30.01M) | (42.08M) | (45.93M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (27.30M) | (30.01M) | (42.08M) | (45.93M) | |
EPS (Basic)
| -1.5228 | -1.6689 | -2.11 | -1.8553 | |
EPS (Basic) Growth
| +19.04% | -9.59% | -26.43% | +12.07% | |
Basic Shares Outstanding
| 17.93M | 17.98M | 19.94M | 24.76M | |
EPS (Diluted)
| -1.5228 | -1.6689 | -2.11 | -1.8553 | |
EPS (Diluted) Growth
| +19.04% | -9.59% | -26.43% | +12.07% | |
Diluted Shares Outstanding
| 17.93M | 17.98M | 19.94M | 24.76M | |
EBITDA
| (25.95M) | (29.74M) | (42.63M) | (30.79M) | |
EBITDA Growth
| +10.98% | -14.60% | -43.35% | +27.79% | |
EBITDA Margin
| -6,938.77% | -19,187.74% | -304,535.71% | -61,570.00% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 7.00 | |
| Number of Ratings | 3 | Current Quarters Estimate | -0.147 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | -0.55 | |
| Last Quarter’s Earnings | -0.05 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.86 | Next Fiscal Year Estimate | -0.77 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 3 | 2 |
| Mean Estimate | -0.15 | -0.19 | -0.55 | -0.77 |
| High Estimates | -0.07 | -0.14 | -0.43 | -0.43 |
| Low Estimate | -0.20 | -0.23 | -0.67 | -1.11 |
| Coefficient of Variance | -46.41 | -24.44 | -21.82 | -62.45 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 4 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Inmune Bio Inc - INMB
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Inmune Bio Inc - INMB
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 20, 2025 | Marcia Allen Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Cory Ellspermann Interim CFO | 30,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Scott Juda Director | 15,975 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Scott Juda Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Scott Juda Director | 108,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Scott Juda Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Scott Juda Director | 108,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Scott Juda Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | 12,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | 32,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | 35,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | 35,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | 19,025 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | 15,975 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |